Liver/Biliary Disorders News

The Global Liver Institute has marked June 8 as International NASH Day, part of a public education campaign to raise awareness and urgency about fatty liver disease and its advanced form, nonalcoholic steatohepatitis.

The use of amoxicillin-clavulanate with prednisolone did not improve 2-month survival compared with prednisolone alone in patients hospitalized with severe alcohol-related hepatitis, according to data in JAMA.

CHICAGO — In a Healio video exclusive, Sarah Khan, MD, explains that patients with advanced liver disease and concurrent fungal infection had worse acute-on-chronic liver failure and higher mortality than those with bacterial infection.

Patients with nonalcoholic steatohepatitis experienced similar mental and work-related impairment as patients with type 2 diabetes mellitus but worse physical status, daily activities impairment and more health care resource use.

In a Healio video exclusive, Jeff Baxter, president and CEO of VBI Vaccines, discusses the current burden of hepatitis B virus infection and shares updates on prevention and treatment strategies for Hepatitis Awareness Month.

Intercept Pharmaceuticals saw a 16% drop in its stock value after an FDA advisory committee declined to approve obeticholic acid in pre-cirrhotic patients with liver fibrosis due to nonalcoholic steatohepatitis.

May is Hepatitis Awareness Month, an annual campaign to raise awareness for viral hepatitis and its impact in the U.S. — and a month-long opening to address the importance of vaccination and testing for viral hepatitis with your patients.

An FDA advisory committee voted against approval for obeticholic acid in pre-cirrhotic patients with liver fibrosis due to nonalcoholic steatohepatitis, citing “concerning” benefit-risk profile.

According to HHS, many of the more than 3.2 million people in the United States with hepatitis B or C are not aware of their infection, raising their risk for severe complications or death and risking further spread of the viruses.

The FDA granted Intercept Pharmaceuticals orphan drug designation for the fixed-dose combination of obeticholic acid and bezafibrate intended for treatment of patients with primary biliary cholangitis.